The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease

SRX246, an orally available CNS penetrant vasopressin (VP) V1a receptor antagonist, was studied in Huntington’s disease (HD) patients with irritability and aggressive behavior in the exploratory phase 2 trial, Safety, Tolerability, and Activity of SRX246 in Irritable HD patients (STAIR). This was a...

Descripción completa

Detalles Bibliográficos
Autores principales: Maibach, Hilda T., Brownstein, Michael J., Hersch, Steven M., Anderson, Karen E., Itzkowitz, Debra E., Damiano, Eve M., Simon, Neal G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605366/
https://www.ncbi.nlm.nih.gov/pubmed/36294700
http://dx.doi.org/10.3390/jpm12101561

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9605366/
https://www.ncbi.nlm.nih.gov/pubmed/36294700
http://dx.doi.org/10.3390/jpm12101561

Ejemplares similares